Loading
LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Lung cancer and Non-small-cell lung cancer.
May play a role in craniofacial and inner ear morphogenesis during embryonic development. May act within the otic vesicle epithelium to control formation of the lateral semicircular canal in the inner ear, possibly by restricting the expression of NTN1.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.91, genetic association 0.03, somatic mutation 0.82). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Bladder Urothelial Carcinoma.
In plain words · LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Lung cancer and Non-small-cell lung cancer.
LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Lung cancer and Non-small-cell lung cancer.
May play a role in craniofacial and inner ear morphogenesis during embryonic development.
No product in this corpus aims at LRIG3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
First described 2003. Earliest sequence paper UniProt cites for the protein: Clark H.F. et al, Genome Res, 2003, "The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment". Source.
Sources: HGNC HGNC:30991 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q6UXM1 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000139263 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.53, lung cancer 0.55 (GraphQL API, CC0)); IntOGen LRIG3 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
May play a role in craniofacial and inner ear morphogenesis during embryonic development. May act within the otic vesicle epithelium to control formation of the lateral semicircular canal in the inner ear, possibly by restricting the expression of NTN1. Location: Cell membrane; Cytoplasmic vesicle membrane (UniProt). Locus 12q14.1 (HGNC).
Query for this target: (TITLE:"LRIG3" OR ABSTRACT:"LRIG3" OR TITLE:"leucine rich repeats and immunoglobulin like domains 3" OR ABSTRACT:"leucine rich repeats and immunoglobulin like domains 3" OR TITLE:"Leucine-rich repeats and immunoglobulin-like domains protein 3" OR ABSTRACT:"Leucine-rich repeats and immunoglobulin-like domains protein 3" OR TITLE:"FLJ90440" OR ABSTRACT:"FLJ90440" OR TITLE:"KIAA3016" OR ABSTRACT:"KIAA3016") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LRIG3, not a curated reading list.